Thrombin biosimilar - Leukocare / Navigo Proteins
Alternative Names: recombinant human thrombin - Navigo Proteins/LEUKOCARE; rhThrombin - Navigo Proteins/LEUKOCARELatest Information Update: 24 Nov 2021
At a glance
- Originator LEUKOCARE; Scil Proteins
- Developer Navigo Proteins
- Class Antifibrinolytics; Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins; Serine endopeptidases
- Mechanism of Action Thrombin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Haemorrhage
Highest Development Phases
- No development reported Haemorrhage
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Haemorrhage in Germany (Topical)
- 15 Nov 2013 Thrombin biosimilar - Leukocare / Scil Proteins is available for licensing as of 30 Oct 2013. www.scilproteins.com
- 30 Oct 2013 Clinical trials in Haemorrhage in Germany (Topical)